Gynecologic Oncology | Vol 140, Iss 1, Pgs 1-190, (January 2016)
Editorial
State of the Science
Meeting Report
Research Reports
Lead article
Original Research Article
Pages 8-14 N.C.
te Grootenhuis, A.G.J. van der Zee, H.C. van Doorn, J. van der Velden,
I. Vergote, V. Zanagnolo, P.J. Baldwin, K.N. Gaarenstroom, E.B. van
Dorst, J.W. Trum, B.F.M. Slangen, I.B. Runnebaum, K. Tamussino, R.H.
Hermans, D.M. Provencher, G.H. de Bock, J.A. de Hullu, M.H.M. Oonk
Highlights
•
Ten year disease-free survival is 91% for patients with a negative sentinel node.
•
Local recurrence rate at ten year after primary treatment is 39.5% for all patients.
•
Disease-specific survival decreases significantly in case a local recurrence occurs.
Entitled to full text
Ovarian Cancer
Original Research Article
Pages 15-21 Amanika
Kumar, Jo Marie Janco, Andrea Mariani, Jamie N. Bakkum-Gamez, Carrie L.
Langstraat, Amy L. Weaver, Michaela E. McGree, William A. Cliby
Highlights
•
Postoperative
complications after primary debulking surgery for advanced epithelial
ovarian cancer are common and predictable based on risk factors.
•
Age, albumin < 3.5 g/dL, surgical complexity, stage, ASA, and BMI influence morbidity and mortality after debulking surgery.
•
Risk stratification may help in pre-operative counseling for patients with advanced ovarian cancer.
Entitled to full text
Original Research Article
Pages 22-28 Iris
J.G. Rutten, Rafli van de Laar, Roy F.P.M. Kruitwagen, Frans C.H.
Bakers, Marieke J.M. Ploegmakers, Teun W.F. Pappot, Regina G.H.
Beets-Tan, Leon F.A.G. Massuger, Petra L.M. Zusterzeel, Toon Van Gorp
Highlights
•
Ovarian cancer models that predict incomplete primary debulking have limited accuracy
•
A radiologist's subjective assessment seems as successful as using a prediction model
•
Prediction models should be interpreted with caution in clinical decision-making
Entitled to full text
Original Research Article
Pages 29-35 Tuulia
Vallius, Anniina Peter, Annika Auranen, Olli Carpén, Jukka Kemppainen,
Jaakko Matomäki, Sinikka Oksa, Pia Roering, Marko Seppänen, Seija
Grénman, Johanna Hynninen
Highlights
•
18 F-FDG-PET/CT can identify histopathological non-responders to NACT in EOC.
•
To obtain histopathological response to NACT, a substantial metabolic activity decrease in 18 F-FDG-PET/CT is required.
•
18 F-FDG-PET/CT -imaging can be helpful when referring patients to IDS or second-line chemotherapy.
Entitled to full text
Original Research Article
Pages 36-41 Geneviève
Bouchard-Fortier, Barry Rosen, Iryna Vyarvelska, Mark Pasetka, Allan
Covens, Lilian T. Gien, Rachel Kupets, Katherine Pulman, Sarah E.
Ferguson, Danielle Vicus
Highlights
•
Randomized controlled trials have demonstrated significant survival benefits with intraperitoneal cisplatin.
•
Intraperitoneal carboplatin has less gastroinstinal, neurologic and hematologic toxicities than intraperitoneal cisplatin
•
High quality studies are evaluating the role of intraperitoneal carboplatin in optimally cytoreduced advanced ovarian cancer.
Entitled to full text
Non-Epithelial Ovarian Cancer
Original Research Article
Pages 48-52 Elizabeth
R. Burton, Mark Brady, Howard D. Homesley, Peter G. Rose, Toshiaki
Nakamura, Joshua P. Kesterson, Jacob Rotmensch, J. Tate Thigpen, Linda
Van Le
Highlights
•
Paclitaxel has activity in recurrent, malignant stromal tumor of the ovary.
•
There was a complete response in 3.2% and partial response in 25.8% of women.
•
Inhibin is not a reliable tumor marker.
Entitled to full text
Original Research Article
Pages 53-57 D.
Callegaro-Filho, D.M. Gershenson, A.M. Nick, M.F. Munsell, P.T.
Ramirez, P.J. Eifel, E.D. Euscher, R.M. Marques, S.M. Nicolau, K.M.
Schmeler
Highlights
•
SCCOHT is a rare disease that affects young women and has a poor prognosis.
•
Adjuvant treatment with multi-agent chemotherapy may improve survival.
•
Radiotherapy may improve outcomes for women with SCCOHT.
Entitled to full text
Endometrial Cancer
Original Research Article
Pages 58-63 Yulan Ren, Xiaowei Huang, Boer Shan, Xiaohua Wu, Xiao Huang, Daren Shi, Huaying Wang
Highlight
•
Concurrent chemoradiotherapy followed by chemotherapy was safe for HREC.
•
Majority of patients (85.7%) completed the planned treatment.
•
Adverse effects were less common in patients who received PC than those with CEP.
Entitled to full text
Original Research Article
Pages 64-69 Pınar
Kemik, Bahadır Saatli, Nuri Yıldırım, Vahit Doğu Kemik, Banu Deveci,
Mustafa Coşan Terek, Semra Koçtürk, Meral Koyuncuoğlu, Uğur Saygılı
Highlights
•
Preoperative HE-4 and YKL-40 levels significantly increase in endometrial cancer.
•
YKL-40 is higher in non-endometrioid than endometrioid histology in early stages.
•
HE4 levels are correlated with poor prognostic factors in endometrial cancer.
Entitled to full text
Gestational Trophoblastic Neoplasia
Original Research Article
Pages 70-75 Y.K.
Eysbouts, J. Bulten, P.B. Ottevanger, C.M.G. Thomas, M.J. ten
Kate-Booij, A.E. van Herwaarden, A.G. Siebers, F.C.G.J. Sweep, L.F.A.G.
Massuger
Highlights
•
An overall incidence rate of 1.67 per 1000 deliveries per year was seen.
•
After an initial rise, incidence rate stabilized from 2004 to 2013.
•
Complete and partial HM reached comparable incidence rates from 2009 onwards.
•
Unspecified HM diagnosis declined significantly, suggesting improved diagnostics.
•
Therefore a true steady incidence rates may have been reached.
Entitled to full text
Cervical Cancer
Original Research Article
Pages 76-82 Emily
S. Wu, Titilope Oduyebo, Lauren P. Cobb, Diana Cholakian, Xiangrong
Kong, Amanda N. Fader, Kimberly L. Levinson, Edward J. Tanner III,
Rebecca L. Stone, Anna Piotrowski, Stuart Grossman, Kara Long Roche
Highlights
•
Patients with cervical cancer treated with chemoradiation experience severe and sustained lymphopenia.
•
Pre-
and post-treatment lymphopenia appear to be associated with shorter
overall survival in women with advanced cervical cancer.
•
Further research is warranted, given that lymphopenia could be a reversible prognostic factor.
Entitled to full text
Health Services Research
Original Research Article
Pages 83-89 Jung-Yun Lee, Janice S. Kwon, David E. Cohn, Younhee Kim, Blair Smith, Tae-Jin Lee, Jae-Weon Kim
Highlights
•
We performed a cost-effectiveness analysis for stage IB cervical cancer.
•
A cost-effectiveness analysis was performed using data from US, Canada, and Korea.
•
MRI-based triage strategy was cost-effective in all countries.
Entitled to full text
Cancer Genetic Testing
Original Research Article
Pages 90-94 S. Lheureux, K. Karakasis, P. Harter, C. Scott, M. Bacon, J. Bryce, N. Le Fur, E. Pujade-Lauraine, A.M. Oza
Highlights
•
BRCA1/2 testing differs worldwide; not all ovarian cancer patients have optimal genetic testing.
•
Identifying BRCA1/2 mutation is a priority, highlighting the interest for collaborative efforts.
•
There is a need for harmonization and complement current recommendations.
Entitled to full text
Quality of Life and Survivorship
Original Research Article
Pages 95-100 Paige E. Tucker, Max K. Bulsara, Stuart G. Salfinger, Jason Jit-Sun Tan, Helena Green, Paul A. Cohen
Highlights
•
Study of 119 women who have undergone risk-reducing salpingo-oophorectomy (RRSO)
•
The prevalence of female sexual dysfunction (FSD) after RRSO was 74%.
•
The prevalence of hypoactive sexual desire disorder (HSDD) after RRSO was 73%.
•
Significant factors were relationship satisfaction, bodily pain, and vaginal estrogen.
•
Serum testosterone and free androgen index are not associated with sexual function.
Entitled to full text
Original Research Article
Pages 101-106 Nora Johansen, Astrid H. Liavaag, Tom G. Tanbo, Alv A. Dahl, Are H. Pripp, Trond M. Michelsen
Highlights
•
We examined sexual activity and functioning after risk-reducing salpingo-oophorectomy
•
The control group consisted of women from the general population
•
RRSO women reported less sexual pleasure and more discomfort than did the controls
•
Among RRSO women, systemic HRT users had less sexual discomfort than did the nonusers
•
No associations between HRT use and sexual pleasure scores were observed
Entitled to full text
Original Research Article
Pages 107-113 Suzanne F. Herling, Ann M. Møller, Connie Palle, Thordis Thomsen
Highlights
•
RALH does not have a prolonged negative effect on general health.
•
Ability to perform work or hobbies was still negatively affected at 5 weeks.
•
Fatigue, pain and gastrointestinal symptoms were negatively affected short term.
Entitled to full text
Original Research Article
Pages 114-119 Lauren
S. Prescott, Andrea S. Dickens, Sandra L. Guerra, Jila M. Tanha,
Desiree G. Phillips, Katherine T. Patel, Katie M. Umberson, Miguel A.
Lozano, Kathryn B. Lowe, Alaina J. Brown, Jolyn S. Taylor, Pamela T.
Soliman, Elizabeth A. Garcia, Charles F. Levenback, Diane C. Bodurka
Highlights
•
We utilized quality improvement methodology to develop an innovative approach to chemotherapy education.
•
Shared medical appointments are a novel concept among oncology provides and patients.
•
Shared medical appointments for oncology patients initiating chemotherapy are both feasible and well accepted.
Entitled to full text
Surgical Techniques
Original Research Article
Pages 120-123 Nina R. Shah, Kristy K. Ward, Steven C. Plaxe, Cheryl C. Saenz, Michael T. McHale
Highlights
•
Clinical gynecologic oncology fellows are exposed to < 1 urinary diversion per year.
•
Diversions with gynecologic oncologist involvement are concentrated at a few centers.
•
Alternative educational methods are needed to train fellows in diversion procedures.
Entitled to full text
Cancer Epidemiology
Original Research Article
Pages 124-130 Linda E. Kelemen, Graham W. Warren, Jennifer M. Koziak, Martin Köbel, Helen Steed
Highlights
•
The interaction between smoking and chemotherapy on survival from ovarian cancer is unknown.
•
Smoking
reduced overall and progression-free survival among patients with
mucinous ovarian cancer receiving adjuvant chemotherapy.
•
Smoking reduced progression-free survival among all ovarian cancer patients receiving neoadjuvant chemotherapy.
Entitled to full text
Translational Medicine
Original Research Article
Pages 131-137 Chi-Hau
Chen, Ming-Kwang Shyu, Shu-Wei Wang, Chih-Hsing Chou, Miao-Juei Huang,
Tzu-Chi Lin, Syue-Ting Chen, Ho-Hsiung Lin, Min-Chuan Huang
Highlights
•
MUC20 is overexpressed in epithelial ovarian cancer.
•
MUC20 enhances aggressive behaviors of epithelial ovarian cancer cells.
•
MUC20 enhances aggressive behaviors of ovarian cancer cells by activating integrin β1 signaling.
Entitled to full text
Original Research Article
Pages 138-144 Matthew
F. Buas, Haiwei Gu, Danijel Djukovic, Jiangjiang Zhu, Charles W.
Drescher, Nicole Urban, Daniel Raftery, Christopher I. Li
Highlights
•
Ovarian cancer is a leading cause of cancer-related mortality among U.S. women.
•
Plasma lipid metabolites differ in women with malignant vs benign serous ovarian tumor.
•
Circulating lipid metabolites may help to boost accuracy of CA125 for clinical triage.
Entitled to full text
Original Research Article
Pages 145-151 Yan Sheng, Hongtao Wang, Dongchen Liu, Cheng Zhang, Yupeng Deng, Fan Yang, Tingguo Zhang, Cuijuan Zhang
Highlights
•
SHP1 methylation has high specificity for diagnosis of endometrial carcinoma.
•
CDH13 methylation plays a role in the precancerous stage of endometrial lesion.
•
Methylation of CDH13 and SHP1 can be reversed by 5-Aza-CdR or TSA.
•
UHRF1 could form a complex with PRMT5 to contribute to the endometrial carcinogenesis.
Entitled to full text
Original Research Article
Pages 152-160 Henry
D. Reyes, Matthew J. Carlson, Eric J. Devor, Yuping Zhang, Kristina W.
Thiel, Megan I. Samuelson, Megan McDonald, Shujie Yang, Jean-Marie
Stephan, Erica C. Savage, Donghai Dai, Michael J. Goodheart, Kimberly K.
Leslie
Highlights
•
We analyzed hormone receptor levels/activity following progestin-containing IUD.
•
PR target gene FOXO1 was significantly downregulated in patients who progressed.
•
FOXO1 mRNA levels may reflect PR function and response to progestin-based therapy.
Entitled to full text
Reviews
Review Article
Pages 161-166 Kathleen N. Moore, Robert S. Mannel
Highlights
•
Molecular sequencing of tumors is now widely available.
•
Therapeutics linked to mutations have improved outcomes for select solid tumors.
•
Mutations of interest may be present in low frequency across solid tumors.
•
The NCI MATCH trial will sequence tumors and match mutations with therapeutics.
Entitled to full text
Review Article
Pages 167-175 Devarati Mitra, Ann H. Klopp, Akila N. Viswanathan
Highlights
•
Stage I endometrial cancer outcomes may not be improved by vaginal brachytherapy after beam (EB + VB).
•
EB + VB may improve local-regional recurrence in high-risk endometrial cancer (e.g . stage II-III).
•
A randomized prospective clinical trial is needed to determine the role for EB + VB
Entitled to full text
Review Article
Pages 176-183 Jamie R. Brewer, Gladys Morrison, M. Eileen Dolan, Gini F. Fleming
Highlights
•
CIPN is a common toxicity of multiple chemotherapy agents.
•
To date there are no reliable genomic biomarkers to predict CIPN.
•
New stem-cell derived neuron models are promising to advance the field.
Entitled to full text
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.